volume 55, issue 4, P272-278 2011
DOI: 10.1590/s0004-27302011000400006
View full text
Sign up to set email alerts

Abstract: ABSTRACTObjective: To assess bone turnover markers (BTM) and bone mineral density (BMD) after discontinuation of alendronate treatment used for five or more years. Subjects and methods: 40 patients (pt) with post-menopausal osteoporosis treated with alendronate (10 mg/d) for at least five years (Group 1, G1) had their medication discontinued. Group 2 (G2): 25 pt treated with alendronate for at least one year. Group 3 (G3): 23 treatment-naïve osteoporotic pt. BMD was evaluated in G1 and G2 at baseline and afte…

Expand abstract